Results 161 to 170 of about 2,580,938 (299)

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

Proceedings of the National Academy of Sciences of the United States of America, 2001
B. Bennett, D. Sasaki, B. Murray, E. O'leary, S. Sakata, Weiming Xu, J. Leisten, Aparna Motiwala, S. Pierce, Y. Satoh*, S. Bhagwat, A. Manning, David W. Anderson   +12 more
semanticscholar   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Immunohistochemical study of Rho-kinase pathway expression in a mouse model of prostate hypertrophy for preliminary study of progressive prostate cancer model establishment. [PDF]

Transl Androl Urol
Yang YM, Kitagawa K, Hirata Y, Moriwaki M, Ono T, Chiang YT, Chen KC, Shigemura K.   +7 more
europepmc   +1 more source

Targeting Mitogen-Activated Protein Kinase/Extracellular Signal–Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases [PDF]

, 2006
Arati Sharma, Melissa Tran, Shile Liang, Arun Sharma, Shantu Amin, Charles D. Smith, Cheng Dong, Gavin P. Robertson   +7 more
openalex   +1 more source

Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma

Molecular Oncology, EarlyView.
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga, María Luz Martinez‐Chantar, Carolina Conter   +2 more
wiley   +1 more source

Enhancing kinase-inhibitor activity and selectivity prediction through contrastive learning. [PDF]

Nat Commun
Tian Y, Lu R, Gong X, Zhao W, Li Y, Wang X, Jia X, Li Q, Yang Y, Tong HHY, Arrais JP, Yao X, Liu H.   +12 more
europepmc   +1 more source

Oxidative Modification of Nuclear Mitogen-activated Protein Kinase Phosphatase 1 Is Involved in Transforming Growth Factor β1-induced Expression of Plasminogen Activator Inhibitor 1 in Fibroblasts [PDF]

, 2010
Rui-Ming Liu, Jinah Choi, Jian-He Wu, Kimberly A. Gaston Pravia, Karen Lewis, Jeffrey D. Brand, Nabora Soledad Reyes de Mochel, David M. Krzywanski, J. David Lambeth, James S. Hagood, Henry Jay Forman, Victor J. Thannickal, Edward M. Postlethwait   +12 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Editorial: Cell and Developmental Signalling in Neuroblastoma

Frontiers in Cell and Developmental Biology, 2023
Rafael Pulido, Rafael Pulido, Caroline E. Nunes-Xavier, Caroline E. Nunes-Xavier   +3 more
doaj   +1 more source

The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib. [PDF]

J Clin Med
Kawczak P, Bączek T.
europepmc   +1 more source